Zydus Lifesciences is currently trading at Rs. 903.00, up by 11.35 points or 1.27% from its previous closing of Rs. 891.65 on the BSE.

The scrip opened at Rs. 904.55 and has touched a high and low of Rs. 904.80 and Rs. 893.15 respectively. So far 4235 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1059.00 on 19-Sep-2025 and a 52 week low of Rs. 835.85 on 02-Apr-2026.

Last one week high and low of the scrip stood at Rs. 953.95 and Rs. 890.00 respectively. The current market cap of the company is Rs. 90198.81 crore.

The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 18.15% and 6.86% respectively.

Zydus Lifesciences’ indirect wholly owned subsidiary -- Amplitude SAS (Amplitude) has acquired 100% share capital of FBC Medical, France, a simplified joint stock.  The acquisition is intended to internalize commercial capabilities currently outsourced to third-party sales agents. By acquiring and integrating the FBC Medical, Amplitude expects to eliminate ongoing commission and business-development fees, thereby reducing long-term selling and distribution costs. The cost of the said acquisition is 700,000 euro.

Zydus Lifesciences (formerly known as Cadila Healthcare) operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.